Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 92

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 92
---
, 2024 and the Company for the period from February 14, 2024 through
September 30, 2024. This pro forma period from January 1, 2024 to September 30, 2024 does not include the Merger transactions that occurred
on-the-line.

    For the Nine Months Ended September 30,  

    2024  

    2025  (Successor)  
    (Pro forma) (Predecessor  and Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $8,048,034  
    $6,156,761  
    $1,891,273  
     30.7%
  
    General and administrative 
     5,988,867  
     7,945,784  
     (1,956,917) 
     (24.6)%
  
    Total operating expenses 
     14,036,901  
     14,102,545  
     (65,644) 
     (0.5)%
  
    Loss from operations 
     (14,036,901) 
     (14,102,545) 
     65,644  
     (0.5)%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     589,223  
     (589,223) 
     (100.0)%
  
    Other income (expenses) 
     248  
     (630,922) 
     631,170  
     (100.0)%
  
    Change in fair value of earnout and derivative liabilities 
     -  
     5,190,117  
     (5,190,117) 
     (100.0)%
  
    Share-based inducement expense 
     (863,550) 
     -  
     (863,550) 
     (100.0)%
  
    Write off of deferred offering costs 
     (500,000) 
     -  
     (500,000) 
     (100.0)%
  
    Interest income (expense), net 
     20,562  
     (22,188) 
     42